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Practical stereoselective synthetic routes to the antihistaminic drug olopatadine and its E-isomer have 
been developed, the key steps being a trans stereoselective Wittig olefination using a nonstabilized 
phosphorus ylide and a stereoselective Heck cyclization. The stereoselectivity of the Wittig reaction 
depends on both the phosphonium salt anion and the cation present in the base used to generate the 
ylide. 
 
 
Olopatadine is a non-sedating histamine H1-receptor antagonist with mast cell stabilizing properties. 
This dual action allows seasonal allergic conjunctivitis and rhinitis signs and symptoms to be 
controlled.
1 
Structurally, olopatadine is a dibenzo[b,e]oxepin derivative bearing a Z-configurated 
(dimethylamino)propylidene substituent and an acetic acid chain at the C-11 and C-2 positions, 
respectively, of the tricyclic system. Previous synthetic approaches to olopatadine
2 
involve the 
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generation of the trisubstituted exocyclic double bond from a tricyclic dibenz[b,e]oxepin ketone, which 
represents a drawback in terms of Z/E stereoselectivity.3 
We herein report short and practical stereoselective syntheses of olopatadine and its E-isomer (trans-
olopatadine), based on a common strategy involving successive stereoselective Wittig and 
intramolecular Heck reactions as the key steps.4 After a Williamson reaction to assemble the benzyl aryl 
ether moiety, the Wittig olefination would lead to the key intermediates 1 or 2, depending on the 
aromatic aldehyde and aryl iodide derivatives used as the starting materials (Scheme 1). Taking into 
account that in particular cases, by choosing the appropriate reaction conditions, high selectivity for (E)- 
and/or (Z)-alkene can be attained in the Wittig reaction of nonstabilized phosphorus ylides with 
aldehydes
5
 and that the Heck reaction usually involves a syn-addition/syn-elimination mechanism,6 the 
above Williamson-Wittig-Heck strategy could provide stereoselective access to both olopatadine and its 
E-isomer. 
SCHEME 1. Synthetic Strategy. A Wittig/Heck Approach to Olopatadine and its E-isomer 
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The starting aldehyde 5 was prepared from 2-iodobenzyl chloride 3 and 3-formyl-4-
hydroxyphenylacetic ester 47 under the reaction conditions indicated in Scheme 2. The Wittig reaction 
from 5 was initially performed using the ylide generated from the commercially available phosphonium 
bromide 6 (X = Br) by treatment with KHMDS in toluene (Table 1, entry 1),
8
 giving a mixture of E/Z 
alkenes in a 1:3 ratio. Similar results were obtained starting from the iodide salt 6 (X = I)
9
 (entry 2). 
Notably, the use of the lithium base LHMDS to generate the ylide from phosphonium iodide 6 (X = I) 
produced a dramatic change in the stereoselectivity of the Wittig reaction, leading to a 9:1 E/Z ratio of 
alkenes 1 in 73% yield (entry 3).
10
 A similar effect, although less pronounced (4:1 E/Z ratio), was 
observed from the bromide salt 6 (X = Br) (entry 4). In contrast, the use of phosphonium chloride 6 (X = 
Cl)11 as the ylide precursor gave poor results in terms of both selectivity and chemical yield (entry 5). 
SCHEME 2. The Wittig Reaction from Aldehyde 5 
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TABLE 1. Stereochemistry Dependence on the Cation in the Wittig Reaction
a 
entry base, M 6, X E/Z ratiob 1, yield (%) 
1 K Br 1:3 60 
2 K I 1:3 85
c 
3 Li I 9:1 73 
4 Li Br 4:1 77
c 
5 Li Cl 1:1.5 37
c 
a
Reaction conditions: aldehyde 5 (0.02 M in anh toluene), phosphonium salt 6 (4.2 equiv), MHMDS 
(4.2 equiv), rt. 
b
Calculated by 
1
H NMR and HPLC. 
c
Calculated by HPLC from the crude reaction mixture. 
 
The above trans selectivity is worthy of comment as Wittig olefination reactions of nonstabilized 
phosphorus ylides with aromatic aldehydes usually produce the thermodynamically less stable cis isomer 
as the major product.
5
 The presence of a nucleophilic group (for instance, amino) in the side chain of 
these ylides causes a shift in the stereochemistry of the alkene product towards the trans isomer,12 whose 
production is also increased by lithium ions.
13
  
The pronounced effect of the lithium cation on alkene stereochemistry was also observed in the 
Wittig reaction from benzaldehyde 9, which was prepared from 2-formylbenzyl bromide 7
14 
and 4-
hydroxy-3-iodophenylacetic ester 8
15 
(Scheme 3). Thus, alkenes 2 were produced in an E/Z ratio of 1:3 
when the ylide was generated in toluene solution from phosphonium iodide 6 (X =I) using KHMDS as 
the base (Table 2, entry 1). Neither the use of THF as the solvent (entry 2) nor starting from the bromide 
salt (entry 3) substantially modified the E/Z ratio. However, when using the lithium base LHMDS to 
generate the ylide from iodide 6 (X = I), the stereoselectivity was reversed, with a significant 
enhancement of E stereochemistry, leading to a E/Z ratio of 3.5:1 (entry 4). 
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SCHEME 3. The Wittig Reaction from Aldehyde 9 
 
 
 
TABLE 2. Stereochemistry Dependence on the Cation in the Wittig Reaction
a
 
entry base, M 6, X
 solvent E/Z ratiob 2, yieldc (%) 
1 K I toluene 1:3 73 
2 K I THF 1:4 64 
3 K Br toluene 1:3 86 
4 Li I toluene 3.5:1 88 
a
Reaction conditions: aldehyde 9 (0.02 M in anh toluene or THF), phosphonium salt 6 (4.2 equiv), 
MHMDS (4.2 equiv), rt. 
bCalculated by 1H NMR and HPLC. 
cCalculated by HPLC from the crude reaction mixture. 
 
From the synthetic standpoint, with four different alkenes now in hand, prepared in acceptable yield 
and good (E-1) to acceptable (Z-1, E-2, Z-2) stereoselectivity, we were ready to tackle the key Heck 
cyclization. The intramolecular Heck reaction from iodo alkene E-1 was performed under solid-liquid 
phase transfer conditions, using a stoichiometric quantity of Bu4NCl as the transfer agent
16
 and K2CO3 
as the base,
17
 in the presence of a catalytic amount of Pd(OAc)2 (without phosphine ligands
18
) in an 
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acetonitrile-water mixture.
19
 A single dibenzoxepin derivative 10, bearing a Z-configurated double bond, 
was formed with complete stereoselectivity in 60% yield. A similar Pd-catalyzed cyclization from iodo 
alkene E-2 stereoselectively afforded E dibenzoxepin 11 in 55% yield. The above results were not 
unexpected and are consistent with a syn-addition of the initially formed arylpalladium intermediate to 
the alkene, with a subsequent syn β-elimination of a hydridopalladium halide, as outlined in Scheme 4.  
SCHEME 4. Stereoselective Heck Reactions 
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However, in contrast with the high stereoselectivity observed in the above Heck arylations from trans 
alkenes E-1 and E-2, the Heck cyclization from cis alkenes Z-1 and Z-2 was not stereoselective, leading 
to mixtures of the cyclized products 10 and 11 (approximate ratios 3:2). 
Finally, alkaline hydrolysis of the cyclized products 10 and 11 furnished the target drug olopatadine 
and its E-isomer, respectively. 
In summary, we have developed practical synthetic routes to the antihistaminic drug olopatadine and 
its E-isomer based on a common strategy involving successive highly stereoselective Wittig olefination 
and Heck cyclization reactions as the key steps. 
 
Experimental Section 
(3-Dimethylaminopropyl)triphenylphosphonium Iodide (6, X = I). A mixture of 3-(dimethylamino)-
1-propyl chloride hydrochloride (20 g, 126 mmol), PPh3 (33 g, 126 mmol), and NaI (19 g, 126 mol) in 
acetonitrile (80 mL) was heated at reflux for 5.5 days. After cooling at rt, H2O–acetonitrile (2:1, 360 
mL) was added, and the mixture was stirred at 45 ºC for 0.5 h. The resulting suspension was filtered, 
solid K2CO3 was added to the filtrate until pH 9-10, and the solution was extracted with CH2Cl2 (3x150 
mL). The combined organic extracts were dried and concentrated, and the resulting oil was dissolved in 
CH2Cl2 (25 mL). AcOEt (120 mL) was added, and the mixture was stirred until the formation of a white 
solid, which was collected by filtration (52 g, 87%): mp 138-141 ºC; 
1
H NMR (300 MHz, CDCl3) δ 
1.75-1.87 (m, 2H), 2.13 (s, 6H), 2.54 (t, J = 5.9 Hz, 2H), 3.65-3.75 (m, 2H), 7.70-7.87 (m, 15H); 13C 
NMR (75.4 MHz, CDCl3) δ 20.4 (d, J = 52.2 Hz), 20.5 (d, J = 3.3 Hz), 45.2 (s), 58.2 (d, J = 16.0 Hz), 
117.9 (d, J = 86.2 Hz), 130.3 (d, J = 12.6 Hz), 133.3 (d, J = 10.5 Hz), 134.9 (d, J = 2.7 Hz); IR (KBr) 
995, 1111, 1438 cm
-1
. Anal. Calcd for C23H27NIP: C, 58.11; H, 5.73; N, 2.95; I, 26.70. Found: C, 58.13; 
H, 5.66; N, 2.90; I, 26.58. 
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(3-Dimethylaminopropyl)triphenylphosphonium Chloride (6, X = Cl). A mixture of 3-
(dimethylamino)-1-propyl chloride hydrochloride (10 g, 63 mmol) and PPh3 (16.5 g, 63 mmol) in 1-
butanol (40 mL) was heated at reflux for 4 days. The mixture was cooled at rt, toluene–Et2O (1:1, 50 
mL) was added, and the solution was kept in the refrigerator for a night. The solid formed was filtered 
and washed with toluene–Et2O and Et2O to give pure 6·HCl (X = Cl) (15.6 g, 59%) as a white powder. 
A solution of this hydrochloride in 2 N aqueous K2CO3  (50 mL) was extracted with CH2Cl2 (3x30 mL). 
The combined organic extracts were dried and concentrated to give an oil, which was cooled in the 
refrigerator for 2 days to afford 6, (X =Cl) as a hygroscopic white solid (12.4 g, 90%): mp 188-191 ºC; 
1
H NMR (300 MHz, CDCl3) δ 1.74-1.87 (m, 2H), 2.12 (s, 6H), 2.53 (t, J = 6.0 Hz, 2H), 3.77-3.89 (m, 
2H), 7.69-7.89 (m, 15H); 
13
C NMR (75.4 MHz, CDCl3) δ 19.9 (d, J = 52.2 Hz), 20.5 (d, J = 3.3 Hz), 
45.0 (s), 58.2 (d, J = 16.0 Hz), 118.0 (d, J = 86.2 Hz), 130.2 (d, J = 12.6 Hz), 133.2 (d, J = 9.9 Hz), 
134.7 (d, J = 2.8 Hz); IR (KBr) 995, 1112, 1434 cm-1. Anal. Calcd for C23H27NClP: C, 71.96; H, 7.09; 
N, 3.65; Cl, 9.24. Found: C, 71.93; H, 7.15; N, 3.52; Cl, 9.45. 
Methyl [3-Formyl-4-(2-iodobenzyloxy)phenyl]acetate (5). A solution of methyl (3-formyl-4-
hydroxyphenyl)acetate (16.7 g, 85.9 mmol) in  acetonitrile (68 mL) was slowly added at rt to a mixture 
of 1-(chloromethyl)-2-iodobenzene (21.7 g, 85.9 mmol), K2CO3 (13.1 g, 94.5 mmol), and NaI (3.22 g, 
21.5 mmol) in acetonitrile (273 mL), and the mixture was heated at reflux for 3 h. The solid was 
separated by filtration and the filtrate was concentrated. The resulting residue was dissolved in toluene 
(330 mL), and the organic solution was washed with 0.1 N aqueous NaOH and H2O, dried, and 
concentrated. The residue was dissolved in acetone (330 mL) and poured into H2O (500 mL). The 
mixture was filtered and the resulting solid was crystallized from toluene-cyclohexane to afford 5 (24.7 
g, 70%): mp 68-70 ºC; 
1
H NMR (300 MHz, CDCl3) δ 3.61 (s, 2H), 3.70 (s, 3H), 5.15 (s, 2H), 7.00-7.10 
(m, 2H), 7.37-7.42 (m, 1H), 7.48-7.51 (m, 2H), 7.77 (d, J = 2.1 Hz, 1H), 7.90 (dd, J = 7.8, 1.2 Hz, 1H), 
10.55 (s, 1H); 
13
C NMR (75.4 MHz, CDCl3) δ 39.9 (CH2), 52.1 (CH3), 74.4 (CH2), 97.2 (C), 113.3 
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(CH), 124.9 (C), 126.9 (C), 128.4 (CH), 128.6 (CH), 129.2 (CH), 129.8 (CH), 136.6 (CH), 138.0 (C), 
139.4 (CH), 159.6 (C), 171.5 (C), 189.2 (CH); IR (NaCl) 1158, 1249, 1683, 1736, 2700, 2900 cm
-1
. 
Anal. Calcd for C17H15IO4: C, 49.78; H, 3.69. Found: C, 49.67; H, 3.66. 
Methyl [4-(2-Formylbenzyloxy)-3-iodophenyl]acetate (9). Operating as above, from 2-
(bromomethyl)benzaldehyde (11 g, 55.3 mmol), methyl (4-hydroxy-3-iodophenyl)acetate (16.1 g, 55 
mmol), K2CO3 (8.36 g, 60.5 mmol), and NaI (2.07 g, 13.8 mmol) in  acetonitrile (220 mL), compound 9 
(18 g, 80%) was obtained after crystallization from acetone–H2O: mp 93-97 ºC; 
1
H NMR (300 MHz, 
CDCl3) δ 3.54 (s, 2H), 3.70 (s, 3H), 5.55 (s, 2H), 6.90 (d, J = 8.4 Hz, 1H), 7.46 (dd, J = 8.2, 2.2 Hz, 
1H), 7.54 (dd, J = 7.8, 7.5 Hz, 1H), 7.67-7.74 (m, 2H), 7.88 (dd, J = 6.0, 1.3 Hz, 1H), 8.08 (d, J = 7.8 
Hz, 1H), 10.15 (s, 1H); 
13
C NMR (75.4 MHz, CDCl3) δ 39.6 (CH2), 52.1 (CH3), 68.6 (CH2), 86.4 (C), 
112.3 (CH), 127.4 (CH), 127.7 (CH), 128.4 (C), 130.4 (CH), 132.4 (C), 134.2 (CH), 134.5 (CH), 138.8 
(C), 140.0 (CH), 156.0 (C), 171.6 (C), 193.4 (CH); IR (KBr) 1252, 1691, 1731, 2750, 2833 cm
-1
. Anal. 
Calcd for C17H15IO4: C, 49.78; H, 3.69; I, 30.94. Found: C, 49.81; H, 3.53; I, 31.24. 
Methyl 3-[4-(Dimethylamino)but-1-enyl]-4-(2-iodobenzyloxy)phenylacetate (1). LHMDS (1 M in 
THF, 51.5 mL, 51.5 mmol) was added dropwise to a suspension of 6 (X = I) (24.3, 51.2 mmol) in 
anhydrous toluene (300 mL), and the resulting mixture was stirred at rt for 1h. A solution of 5 (5.00 g, 
12.2 mmol) in anhydrous toluene (170 mL) was added and the resulting mixture was stirred at rt for 2.5 
h. The reaction was quenched with H2O (150 mL), and the aqueous layer was extracted with toluene. 
The combined organic extracts were extracted with 2 N aqueous HCl (150 mL), and then solid K2CO3 
was added to the aqueous phase until pH 9. The alkaline solution was extracted with EtOAc, and the 
extracts were dried and concentrated. Column chromatography (Al2O3, hexane–EtOAc 95:5 to 75:25) 
afforded compound 1 (4.26 g, 73%; E/Z 9:1) as an oil. Pure samples of both isomers were obtained after 
additional column chromatography. 
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Data for E-1: 
1
H NMR (300 MHz, CDCl3) δ 2.27 (s, 6H), 2.39-2.45 (m, 4H), 3.55 (s, 2H), 3.68 (s, 3H), 
5.04 (s, 2H), 6.18-6.29  (m, 1H), 6.81 (d, J = 8.7 Hz, 1H), 6.84 (d, J = 16.2 Hz, 1H), 6.99-7.09 (m, 2H), 
7.34-7.39 (m, 2H), 7.50 (dd, J = 7.5, 1.8 Hz, 1H), 7.86 (dd, J = 7.9, 1.2 Hz, 1H); 13C NMR (75.4 MHz, 
CDCl3) δ 31.8 (CH2); 40.4 (CH2), 45.4 (2CH3); 52.0 (CH3), 59.4 (CH2), 74.4 (CH2), 96.9 (C), 112.8 
(CH), 125.1 (CH), 126.6 (C), 127.2 (C), 127.3 (CH), 128.3 (CH), 128.4 (CH), 128.6 (CH), 129.3 (CH), 
129.4 (CH), 139.1 (CH), 139.2 (C), 154.1 (C), 172.2 (C); IR (NaCl) 1245, 1737 cm
-1
. Anal. Calcd for 
C22H26NIO3: C, 55.12; H, 5.47; N, 2.92. Found: C, 55.12; H, 5.48; N, 2.83.  
Data for Z-1: 
1
H NMR (300 MHz, CDCl3) δ 2.22 (s, 6H), 2.36-2.51 (m, 4H), 3.57 (s, 2H), 3.68 (s, 3H), 
5.02 (s, 2H), 5.74 (dt, J = 11.4, 6.8 Hz, 1H), 6.67 (d, J = 11.4 Hz, 1H); 6.84 (d, J = 8.7 Hz, 1H), 6.97-
7.13 (m, 2H), 7.20 (d, J = 1.8 Hz, 1H), 7.32-7.40 (m, 1H), 7.48-7.51 (m, 1H), 7.84 (dd, J = 7.8, 1.2 Hz, 
1H); 
13
C NMR (75.4 MHz, CDCl3) δ 27.1 (CH2), 40.4 (CH2), 45.3 (2CH3), 52.0 (CH3), 59.4 (CH2), 74.2 
(CH2), 96.7 (C), 112.3 (CH), 125.2 (CH), 126.0 (C), 127.0 (C), 128.3 (2CH), 128.7 (CH), 129.3 (CH), 
130.4 (CH), 130.9 (CH), 139.0 (CH), 139.2 (C), 154.9 (C), 172.1 (C); IR (NaCl) 1244, 1738 cm
-1
. Anal. 
Calcd for C22H26NIO3: C, 55.12; H, 5.47; N, 2.92. Found: C, 55.17; H, 5.54; N, 2.87. 
Methyl 4-{2-[4-(Dimethylamino)but-1-enyl]benzyloxy}-3-iodophenylacetate (2). Operating as above, 
from aldehyde 9, under the reaction conditions of Table 2, mixtures of E-2 and Z-2 were obtained. 
Column chromatography (Al2O3, hexane–EtOAc 95:5 to 75:25) afforded the pure isomers as oils. 
Data for E-2: 
1
H NMR (300 MHz, CDCl3) δ 2.27 (s, 6H), 2.41-2.44 (m, 4H), 3.52 (s, 2H), 3.69 (s, 3H), 
5.14 (s, 2H), 6.08-6.19 (m, 1H), 6.72 (d, J = 15.6 Hz, 1H), 6.83 (d, J = 8.4 Hz, 1H), 7.18-7.31 (m, 3H), 
7.46-7.53 (m, 2H), 7.71 (d, J = 2.1 Hz, 1H); 13C NMR (75.4 MHz, CDCl3) δ 31.8 (CH2), 39.6 (CH2), 
45.5 (2CH3), 52.1 (CH3), 59.3 (CH2), 69.4 (CH2), 86.7 (C), 112.5 (CH), 126.1 (CH), 127.0 (CH), 127.5 
(CH), 128.2 (CH), 128.2 (C), 128.4 (CH), 130.2 (CH), 131.5 (CH), 132.6 (C), 136.6 (C), 140.1 (CH), 
156.3 (C), 171.7 (C); IR (NaCl) 1249, 1488, 1738 cm
-1
. Anal. Calcd for C22H26NIO3: C, 55.12; H, 5.47; 
I, 26.47; N, 2.92. Found: C, 54.97; H, 5.43; I, 26.63; N, 2.85. 
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Data for Z-2: 
1
H NMR (300 MHz, CDCl3) δ 2.17 (s, 6H), 2.29-2.35 (m, 4H), 3.51 (s, 2H), 3.68 (s, 3H), 
5.05 (s, 2H), 5.76-5.85 (m, 1H), 6.60 (d, J = 11.40 Hz, 1H), 6.78 (d, J = 8.1 Hz, 1H), 7.16-7.31 (m, 4H), 
7.63-7.66 (m, 1H), 7.70 (d, J = 2.4 Hz, 1H); 13C NMR (75.4 MHz, CDCl3) δ 26.9 (CH2), 39.6 (CH2), 
45.3 (2CH3), 52.0 (CH3), 59.3 (CH2), 68.9 (CH2), 86.6 (C), 112.2 (CH), 127.1 (CH), 127.4 (2CH), 127.5 
(CH), 128.1 (C), 129.1 (CH), 130.1 (CH), 131.8 (CH), 134.0 (C), 135.6 (C), 140.0 (CH), 156.3 (C), 
171.6 (C); IR (NaCl) 1250, 1489, 1738 cm
-1
. Anal. Calcd for C22H26NIO3: C, 55.12; H, 5.47; I, 26.47; 
N, 2.92. Found: C, 55.21; H, 5.68; I, 25.16; N, 2.87. 
(Z)-Methyl 11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetate (10). A 
mixture of the compound of E-1 (600 mg, 1.25 mmol), K2CO3 (436 mg, 3.15 mmol), and Bu4NCl (349 
mg, 1.25 mmol) in 10:1 acetonitrile–H2O (24 mL) was stirred at rt for 15 min Pd(OAc)2  (57 mg, 0.25 
mmol) was added, and the mixture was stirred at 60 ºC for 24 h. The solvent was removed under 
reduced pressure, and the resulting residue was dissolved in EtOAc (40 mL) and washed with saturated 
aqueous NaHCO3 and aqueous NaCl solutions. The organic phase was dried, filtered, and concentrated. 
Column chromatography (Al2O3, hexane–EtOAc 95:5 to 75:25) of the residue afforded 10 (264 mg, 
60%) as an oil: 1H NMR (300 MHz, CDCl3) δ 2.22 (s, 6H), 2.41-2.46 (m, 2H), 2.56-2.63 (m, 2H), 3.52 
(s, 2H), 3.66 (s, 3H), 5.18 (br, 2H), 5.71  (t, J = 7.2 Hz, 1H), 6.80 (d, J = 8.4 Hz, 1H), 7.02-7.09 (m, 
2H), 7.22-7.30 (m, 4H); 
13
C NMR (75.4 MHz, CDCl3) δ 28.0 (CH2), 40.2 (CH2), 45.4 (2CH3), 51.9 
(CH3), 59.4 (CH2), 70.3 (CH2), 119.6 (CH), 123.8 (C), 125.5 (C), 126.1 (CH), 127.3 (2CH), 128.9 (CH), 
129.8 (CH), 130.7 (CH), 131.9 (CH), 133.5 (C), 139.5 (C), 145.5 (C), 154.4 (C), 172.0 (C); IR (NaCl) 
1225, 1489, 1739 cm
-1
. Anal. Calcd for C22H25NO3 · 1/4H2O: C, 74.24; H, 7.22; N, 3.94. Found: C, 
74.59; H, 7.14; N, 3.77. 
(E)-Methyl 11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetate (11). 
Operating as in the above preparation of 10, from E-2 (100 mg, 0.21 mmol), compound 11 (40 mg, 
55%) was obtained as an oil after column chromatography (Al2O3, hexane–EtOAc 95:5 to 75:25): 
1
H 
 12  
NMR (300 MHz, CDCl3) δ 2.16 (s, 6H), 2.28-2.43 (m, 4H), 3.53 (s, 2H), 3.67 (s, 3H), 4.78 (br, 1H), 
5.54 (br, 1H), 6.03 (t, J = 6.9 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 7.20 (dd, J = 8.5, 2.2 Hz, 1H), 7.17-
7.37 (m, 5H); 13C NMR (75.4 MHz, CDCl3) δ 27.7 (CH2), 40.2 (CH2), 45.3 (2CH3), 52.0 (CH3), 59.2 
(CH2), 70.0 (CH2), 119.3 (CH), 126.1 (C), 127.2 (C), 127.7 (CH), 127.8 (CH), 128.1 (CH), 128.4 (CH), 
129.6 (CH), 130.2 (CH), 130.7 (CH), 134.1 (C), 139.6 (C), 141.0 (C), 154.1 (C), 172.2 (C); IR (NaCl) 
1224, 1489, 1738 cm
-1
. Anal. Calcd for C22H25NO3: C, 75.19; H, 7.17; N, 3.99. Found: C, 74.82; H, 
7.14; N, 3.81. 
(Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic Acid 
Hydrochloride. 5 N aqueous NaOH (6.2 mL, 31.0 mmol) was added to a solution of 10 (3.32 g, 9.45 
mmol) in MeOH (105 mL) and H2O (21 mL). The mixture was stirred at rt for 3 h, neutralized with 2 N 
aqueous HCl, and concentrated to dryness. The resulting residue was dissolved in H2O and the solution 
was filtered through an ionic exchange resin DIAION HP-20 (H2O until negative test of AgNO3 and 
then MeOH as eluents).  The methanolic fractions gave olopatadine (2.64 g, 83%). 37% HCl (1 mL, 
12.0 mmol) was added to a stirred solution of the above olopatadine in THF (65 mL), and the mixture 
was stirred for 5 min. The solid formed was filtered and suspended in acetone (60 mL). The suspension  
was refluxed for 30 min, cooled, and filtered to give olopatadine hydrochloride as a solid (2.33 g, 66% 
overall): mp 231-233 ºC (dec); 1H NMR (300 MHz, CD3OD) δ  2.86 (s, 6H), 2.83-2.91 (m, 2H), 3.28-
3.34 (m, 2H), 3.57 (s, 2H), 5.19 (br, 2H), 5.67 (t, J = 7.3 Hz, 1H), 6.81 (d, J = 8.4 Hz, 1H), 7.07-7.13 
(m, 2H), 7.26-7.37 (m, 4H); 
13
C NMR (75.4 MHz, CD3OD) δ 26.4 (CH2), 40.5 (CH2), 43.4 (2CH3), 58.0 
(CH2), 71.5 (CH2), 120.3 (CH), 124.8 (C), 126.5 (CH), 127.0 (CH), 128.4 (C), 128.5 (CH), 129.0 (CH), 
130.1 (CH), 131.7 (CH), 132.8 (CH), 135.1 (C), 144.5 (C), 145.6 (C), 155.9 (C), 175.7 (C); IR (KBr) 
1225, 1491, 1716, 2927 cm
-1
. Anal. Calcd for C21H24NClO3 · H2O: C, 64.36; H, 6.69; N, 3.57. Found: C, 
64.59; H, 6.30; N, 3.63. 
 13  
(E)-11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic Acid 
Hydrochloride. Operating as above, from ester 11 (973 mg, 2.77 mmol), trans-olopatadine 
hydrochloride was obtained as a white solid (728 mg, 70%): mp 170-173 ºC; 1H NMR (300 MHz, 
CD3OD) δ 2.56-2.63 (m, 2H), 2.75 (s, 6H), 3.13 (t, J = 7.6 Hz, 2H), 3.53 (s, 2H), 4.78 (br, 1H), 5.51 (br, 
1H), 5.98 (t, J = 7.2 Hz, 1H), 6.69 (d, J = 8.4 Hz, 1H), 7.06 (dd, J = 8.3, 2.3 Hz, 1H), 7.25-7.44 (m, 
5H); 
13
C NMR (75.4 MHz, CD3OD) δ 26.0 (CH2), 40.8 (CH2), 43.3 (2CH3), 57.9 (CH2), 70.9 (CH2), 
120.3 (CH), 125.9 (CH), 127.6 (C), 128.5 (C), 128.6 (CH), 129.5 (2CH), 130.0 (CH), 131.5 (CH), 132.0 
(CH), 135.8 (C), 141.3 (C), 144.2 (C), 155.6 (C), 175.7 (C); IR (KBr) 1223, 1484, 1725, 2960 cm
-1
. 
Anal. Calcd for C21H24NClO3 · H2O: C, 64.36; H, 6.69; N, 3.57. Found: C, 64.66; H, 6.47; N, 3.56. 
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